New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib ' s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
Late-breaking analysis from pivotal INDIGO Phase 3 trial demonstrates vorasidenib led to tumor shrinkage in IDH1/2-mutant diffuse glioma
First data from Phase 1 trial show the safety and tolerability of vorasidenib plus KEYTRUDA®...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials